In Vivo genetic screens of patient-derived tumors revealed unexpected frailty of the transformed phenotype

Cancer Discovery

Volumn 6, Issue 6, 2016, Pages 650-663

  Bossi, Daniela ^a   Cicalese, Angelo ^a   Dellino, Gaetano I ^a,b   Luzi, Lucilla ^a   Riva, Laura ^c   D’Alesio, Carolina ^a   Diaferia, Giuseppe R ^a   Carugo, Alessandro ^a,d   Cavallaro, Elena ^a   Piccioni, Rossana ^a   Barberis, Massimo ^a   Mazzarol, Giovanni ^a   Testori, Alessandro ^a   Punzi, Simona ^a   Pallavicini, Isabella ^a   Tosti, Giulio ^a   Giacó, Luciano ^a   Melloni, Giorgio ^a   Heffernan, Timothy P ^d   Natoli, Gioacchino ^a   Draetta, Giulio F ^d   Minucci, Saverio ^a,b   Pelicci, Piergiuseppe ^a,b   Lanfrancone, Luisa ^a   more..

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; SHORT HAIRPIN RNA; DNA BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; MLL2 PROTEIN, HUMAN; NRAS PROTEIN, HUMAN; PROTEIN BINDING; SMALL INTERFERING RNA; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAZ1B GENE; CARCINOGENESIS; CELL MIGRATION; CHD4 GENE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; EPIGENETICS; FRAILTY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC SCREENING; GROWTH INHIBITION; HISTONE LYSINE N METHYLTRANSFERASE GENE; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; MALE; METASTATIC MELANOMA; MOUSE; NONHUMAN; NRAS GENE; PHENOTYPE; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMARCA4 GENE; SOMATIC MUTATION; TUMOR GROWTH; UPREGULATION; XENOGRAFT; ANIMAL; BIOLOGY; CELL TRANSFORMATION; DISEASE MODEL; ENHANCER REGION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; METASTASIS; NEOPLASMS; PROCEDURES; REPRODUCIBILITY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GTP PHOSPHOHYDROLASES; HETEROGRAFTS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MEMBRANE PROTEINS; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; PHENOTYPE; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING;

EID: 85012027045     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-1200     Document Type: Article

References (41)

1. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011; 331: 1553-8.
2. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-58.
3. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 2013;14:703-18.
4. Rubio-Perez C, Tamborero D, Schroeder MP, Antolin AA, Deu-Pons J, Perez-Llamas C, etal. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer cell 2015;27:382-96.
5. Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, etal. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A 2015;112:232-7.
6. Beronja S, Janki P, Heller E, Lien WH, Keyes BE, Oshimori N, etal. RNAi screens in mice identify physiological regulators of oncogenic growth. Nature 2013; 501: 185-90.
7. Meacham CE, Lawton LN, Soto-Feliciano YM, Pritchard JR, Joughin BA, Ehrenberger T, et al. A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth. Genes Dev 2015; 29: 483-8.
8. Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Jaras M, Puram RV, etal. In vivo RNAi screening identifies a leukemia-specifi c dependence on integrin beta 3 signaling. Cancer cell 2013;24:45-58.
9. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011;476:346-50.
10. Possik PA, Muller J, Gerlach C, Kenski JC, Huang X, Shahrabi A, etal. Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition. Cell reports 2014;9:1375-86.
11. Schramek D, Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, etal. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science 2014;343:309-13.
12. Scuoppo C, Miething C, Lindqvist L, Reyes J, Ruse C, Appelmann I, et al. A tumour suppressor network relying on the polyamine-hypusine axis. Nature 2012; 487: 244-8.
13. Wolf J, Muller-Decker K, Flechtenmacher C, Zhang F, Shahmoradgoli M, Mills GB, et al. An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation. Oncogene 2014;33:4273-8.
14. Wuestefeld T, Pesic M, Rudalska R, Dauch D, Longerich T, Kang TW, etal. A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell 2013;153:389-401.
15. Lo RS, Shi H. Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma. Methods Mol Biol 2014;1102:163-74.
16. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013;49:1297-304.
17. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, etal. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010;18:510-23.
18. Barnett C, Krebs JE. WSTF does it all: a multifunctional protein in transcription, repair, and replication. Biochem Cell Biol 2011; 89: 12-23.
19. Curtis CD, Griffin CT. The chromatin-remodeling enzymes BRG1 and CHD4 antagonistically regulate vascular Wnt signaling. Mol Cell Biol 2012;32:1312-20.
20. Ford DJ, Dingwall AK. The cancer COMPASS: navigating the functions of MLL complexes in cancer. Cancer Genet 2015;208:178-91.
21. Guo C, Chang CC, Wortham M, Chen LH, Kernagis DN, Qin X, et al. Global identification of MLL2-targeted loci reveals MLL2’s role in diverse signaling pathways. Proc Natl Acad Sci U S A 2012; 109: 17603-8.
22. Guo C, Chen LH, Huang Y, Chang CC, Wang P, Pirozzi CJ, et al. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget 2013;4:2144-53.
23. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010;23:746-59.
24. http://www.qiagen.com/ingenuity.
25. Fagiani E, Giardina G, Luzi L, Cesaroni M, Quarto M, Capra M, et al. RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas. Cancer Res 2007;67:3064-73.
26. Yang D, Tao J, Li L, Kedei N, Toth ZE, Czap A, et al. RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma. Oncogene 2011;30:4590-600.
27. Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 2005;434:786-92.
28. Lee JE, Wang C, Xu S, Cho YW, Wang L, Feng X, et al. H3K4 mono and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. eLife 2013;2:e01503.
29. Bogdanovic O, Fernandez-Minan A, Tena JJ, de la Calle-Mustienes E, Hidalgo C, van Kruysbergen I, et al. Dynamics of enhancer chromatin signatures mark the transition from pluripotency to cell specification during embryogenesis. Genome Res 2012;22:2043-53.
30. Bonn S, Zinzen RP, Girardot C, Gustafson EH, Perez-Gonzalez A, Delhomme N, et al. Tissue-specifi c analysis of chromatin state identifies temporal signatures of enhancer activity during embryonic development. Nat Genet 2012;44:148-56.
31. Krivega I, Dean A. Enhancer and promoter interactions-long distance calls. Curr Opin Genet Dev 2012;22:79-85.
32. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013;154:442-51.
33. Cowley GS, Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data 2014;1:140035.
34. Gonzalez-Perez A, Jene-Sanz A, Lopez-Bigas N. The mutational land- scape of chromatin regulatory factors across 4,623 tumor samples. Genome Biol 2013;14:r106.
35. Lee JJ, Murphy GF, Lian CG. Melanoma epigenetics: novel mechanisms, markers, and medicines. Lab Invest 2014;94:822-38.
36. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14:249-56.
37. Jinushi M, Nakazaki Y, Carrasco DR, Draganov D, Souders N, Johnson M, et al. Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment. Cancer Res 2008;68:8889-98.
38. Tibaldi L, Leyman S, Nicolas A, Notebaert S, Dewulf M, Ngo TH, et al. N ew blocking antibodies impede adhesion, migration and survival of ovarian cancer cells, highlighting MFGE8 as a potential therapeutic target of human ovarian carcinoma. PLoS One 2013;8:e72708.
39. Dave B, Granados-Principal S, Zhu R, Benz S, Rabizadeh S, Soon-Shiong P, et al. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proc Natl Acad Sci U S A 2014;111:8838-43.
40. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory- efficient alignment of short DNA sequences to the human genome. Genome Biol 2009;10:R25.
41. Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, et al. C omparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One 2012;7:e46536.